Rimonabant: Just an Antiobesity Drug? Current Evidence on Its Pleiotropic Effects
Open Access
- 27 February 2007
- journal article
- review article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Molecular Pharmacology
- Vol. 71 (6), 1445-1456
- https://doi.org/10.1124/mol.106.033118
Abstract
The advent of the highly selective cannabinoid receptor (CB1) antagonist, rimonabant (SR141716; Acomplia) can revolutionize the ability of the clinicians to manage obesity. Large-scale clinical trials have demonstrated that rimonabant therapy can reduce obesity. Although, the precise mechanisms of action of rimonabant have to be further dissected, it is emerging, from both preclinical and clinical research, that not only is rimonabant an antiobesity drug, but also its pleiotropic functions affect a broad range of diseases, from obesity-related comorbidities to drug dependence and cancer. Here we review recent data from the literature and discuss the full pharmacological potential of this drug.Keywords
This publication has 100 references indexed in Scilit:
- The Cannabinoid CB1 Receptor Antagonist Rimonabant (SR141716) Inhibits Human Breast Cancer Cell Proliferation through a Lipid Raft-Mediated MechanismMolecular Pharmacology, 2006
- Anandamide inhibits adhesion and migration of breast cancer cellsExperimental Cell Research, 2006
- Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphomaFEBS Letters, 2005
- Cannabinoid CB1 antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent ratsNeuropharmacology, 2005
- The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the mouse elevated T-mazeNeuroscience Letters, 2005
- Inverse agonism and neutral antagonism at cannabinoid CB1 receptorsLife Sciences, 2005
- Cannabinoids and the human uterus during pregnancyAmerican Journal of Obstetrics and Gynecology, 2004
- Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high‐dose levodopa in the reserpine‐treated rat model of Parkinson's diseaseMovement Disorders, 2002
- The Role of TNF-α in Human Adipose Tissue: Prevention of Weight Gain at the Expense of Insulin Resistance?Hormone and Metabolic Research, 1999
- SR141716A, a potent and selective antagonist of the brain cannabinoid receptorFEBS Letters, 1994